$1.42
-2.1%OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
OSTX • NYSE
| OS Therapies Incorporated Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||
-8.9M | -7.8M | -6.3M | -7.4M | -6B | |
2.8K | 4.2K | 805.0 | 805.0 | 67K | |
268.3K | 0.0 | 0.0 | 0.0 | 0.0 | |
1.5M | 2.8M | 1.5M | 2.4M | 2.7B | |
-129.6K | 2M | 947.3K | 574.7K | 964.4M | |
-7.3M | -3M | -3.8M | -4.4M | -2.4B | |
INVESTING ACTIVITIES | |||||
(0.0) | (0.0) | (0.0) | -11.9K | -2M | |
0.0 | 1.1K | 230.9K | 212.4K | 160.3M | |
(0.0) | (1.1K) | (230.9K) | (200.5K) | (158.3M) | |
FINANCING ACTIVITIES | |||||
5.2M | 0.0 | 0.0 | 0.0 | 2.1M | |
1.5M | 3.2M | 3.8M | 3M | 3.5B | |
-31.3M | (0.0) | (0.0) | (0.0) | (0.0) | |
31.3M | -284.2K | -172K | 100K | 0.0 | |
12.8M | 2.9M | 3.7M | 3.1M | 3.5B | |
CASH FLOW SUMMARY | |||||
0.0 | 0.0 | 0.0 | 0.0 | 9.9M | |
5.5M | -132.5K | 90.7K | -1.2M | 1.2B | |
39K | 171.5K | 80.8K | 1.2M | 0.0 | |
5.5M | 39K | 171.5K | 80.8K | 1.2B | |
-7.3M | -3M | -3.8M | -4.4M | -2.4B |
OSTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 18, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 10, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 21, 2025 | October 21, 2025 | 2025 |
Continue your OSTX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.